hrp0095p1-276 | Fat, Metabolism and Obesity | ESPE2022

Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects with Lipodystrophy

Brite Brianna , Abel Brent , Cochran Elaine , Brown Rebecca

Metreleptin is a leptin analog used to treat metabolic complications of lipodystrophy, a set of rare disorders characterized by generalized (GL) or regional (PL) deficiency of adipose tissue, resulting in insulin resistance, diabetes, dyslipidemia, steatohepatitis, and reproductive dysfunction. Metreleptin increases fertility, particularly in GL; spontaneous pregnancy without metreleptin was reported in only 4 patients with GL. Risks of metreleptin suggested by rodent studies ...

hrp0084p3-1226 | Thyroid | ESPE2015

A Rare Adverse Effect of Radioactive Iodine Therapy in a Child with Graves’ Disease

Walsh Elizabeth , Brown Marcie Drury , Crudo David , Constantaocs Cathrine

Background: Radioactive iodine (RAI) therapy has become the preferred treatment for GravesÂ’ disease in children. Its use has found favour due to the risk of adverse effects in medical management and the invasiveness of thyroidectomy. Side effects of RAI in adults are well-documented and include dry mouth, sore throat, and neck pain. With its relatively recent application to paediatric patients, there is not a complete understanding of adverse effects in the paediatric pop...

hrp0089p3-p119 | Diabetes & Insulin P3 | ESPE2018

A Rare Cause of Severe Anemia in a Patient with Type 1 Diabetes

Piekarski Robert , Bury Anna , Beń-Skowronek Iwona

Introduction: Anemia in children is still quite common, sometimes it is a secondary symptom of another rare disorder. Rendu-Osler-Weber disease, a genetically determined haemorrhagic diathesis, is characterized by the occurrence of vascular malformations leading to bleeding from the nose, skin and mucous membranes and to various internal organs. Diagnosis facilitates the occurrence of the disease in relatives of the first degree, however, due to the progressive nature of vascu...

hrp0082p3-d3-805 | Gonads and Gynaecology | ESPE2014

The Genotypic and Phenotypic Variability of Mixed Gonadal Dysgenesis

Grimbly Chelsey , Couch Robert , Girgis Rose

Background: Mixed gonadal dysgenesis is most commonly associated with 45,XO/46,XY karyotype.Objective and hypotheses: We report three cases that illustrate the genotype and phenotype variability of mixed gonadal dysgenesis.Methods: Data was extracted from Pediatric Endocrinology charts in a tertiary care centre after consenting the parents.Results: i) A 13 year old patient, 45,XO/46,X, isodicentric Y chromoso...

hrp0095p2-139 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2022

A stormy neonatal course

Brown Katie , Kaninde Abhidhamma , Law James , Nadar Ruchi , Saraff Vrinda , Mohamed Zainaba

Introduction: Neonatal thyrotoxicosis (NT) is rare but potentially life-threatening condition with high mortality risk due to cardiac failure(12-20%). Affected neonates are born to mothers with underlying thyroid pathology. Estimated prevalence of trans-placental transfer of thyroid antibodies occurs 1 in every 70 pregnancies with Graves’ disease. Symptoms in the neonate usually manifest by 10 days of life but this can be as late as day 45. We discuss tw...

hrp0084p2-415 | GH & IGF | ESPE2015

The Pharmacokinetics and Pharmacodynamics of TV-1106, a Once Weekly GH Supplement: Results from a Phase 2 Study of TV-1106 in Adults with GH Deficiency

Cohen-Barak Orit , Christiansen Jens Sendahl , Bidlingmaier Martin , Brown Kurt , Sakov Anat , Anscheutz Gaya , Butler Kathleen

Background: TV-1106 (Teva Pharmaceuticals Ltd) is a genetically fused recombinant GH (rhGH) and human serum albumin in development as a once weekly treatment of GH deficiency (GHD) in children and adults. TV-1106 has an extended duration of action compared to daily rhGH treatment, reducing the frequency of injections.Objective and hypotheses: The pharmacokinetics and pharmacodynamics of TV-1106 were evaluated in phase 2 study using non-compartmental anal...

hrp0084p2-553 | Thyroid | ESPE2015

Efficacy of Supplemental Liothyronine for Patients with Congenital Hypothyroidism and Pituitary Resistance to Thyroid Hormone

Paone Laura , Fleisch Abby F , Feldman Henry , Cappa Marco , Brown Rosalind , Wassner Ari J

Background: Recent guidelines recommend levothyroxine (LT4) monotherapy for all infants with congenital hypothyroidism (CH). However, up to one-third of patients have pituitary resistance to thyroid hormone and, to normalize their TSH, require supranormal circulating levels of T4. Liothyronine (T3) has been proposed as a supplemental therapy for such patients, but data demonstrating its use and efficacy are limited.Object...

hrp0095p1-91 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2022

Global microRNA and protein expression in human term placenta may improve our understanding of fetal growth

Östling Hanna , Lodefalk Maria , Backman Helena , Kruse Robert

Introduction: The placenta is an endocrine organ vital to fetal growth. It has multiple functions: pregnancy maintenance, nutrient and oxygen transport to the fetus, and removal of waste products among other functions. MicroRNAs (miRNAs) and proteins are significant mediators of these functions. A description of their global expression in healthy placenta may increase our understanding of the molecular biological pathways that are important for normal fetal gr...

hrp0089fc2.6 | Bone, Growth Plate & Mineral Metabolism 1 | ESPE2018

Final Height is Negatively Related to Disease Burden in Mitochondrial Disease

Boal Rachel , Ng Yi Shiau , McFarland Robert , Cheetham Tim

Context: Abnormal growth and short stature are observed in patients with mitochondrial disease but it is unclear whether there is a relationship between growth, stature and muscle phenotype.Objectives: To examine growth and final height in patients with genetically confirmed mitochondrial disease, to describe growth patterns in the principle underlying genetic subgroups and to establish whether stature is related to disease severity.<p class="abstext...

hrp0086fc9.3 | Pathophysiology of Disorders of Insulin Secretion | ESPE2016

Gastrointestinal Dysmotility and Pancreatic Exocrine Insufficiency as Newly Recognised Possible Features in Two Siblings with Donohue Syndrome

Kostopoulou Eirini , Shah Pratik , Semple Robert , Ahmad Noman , Hussain Khalid

Background: Donohue syndrome is a rare congenital syndrome of insulin-resistance and abnormal glucose homeostasis, caused by mutations in the insulin receptor (INSR) gene. It is characterized by specific phenotypic and clinical features and the diagnosis is based on clinical, biochemical and genetic criteria.Case reports: We report two siblings with Donohue syndrome with typical dysmorphic features and multiple clinical and biochemical characteristics. G...